Mid-Atlantic BioTherapeutics, Inc. Launches $5 Million Regulation D 506(c) Funding Round to Support Clinical Program Acceleration and Expand the Company's Global Reach and Market Presence

Barchart · 10/15 09:30

DOYLESTOWN, Pa., Oct. 15, 2024 /PRNewswire/ -- Mid-Atlantic BioTherapeutics, Inc. (the "Company"), a clinical-stage biotechnology company specializing in cutting-edge immunotherapies and central nervous system ("CNS") disorder treatments, today announced the commencement of a fundraising round under Regulation D, Rule 506(c) of the Securities Act of 1933, as amended (the "Securities Act"). The Company is offering up to $5 million in common stock on a best-efforts basis, with a minimum investment of $50,000.

Read more at prnewswire.com